---
search:
  boost: 2 
---

# Ulcerative Colitis

This is a subcategory of Gastrointestinal Agents.

## Formulary

### Preferred

| Preferred                      | Generic Name           | Quantity | Time (Days) |
| :----------------------------- | :--------------------- | :------: | :---------: |
| Balsalazide Disodium           |                        |          |             |
| Budesonide ER Tab <sup>QL<sup> | Budesonide Tab ER 9 MG |    56    |     90      |
| Mesalamine DR Cap, Tab         |                        |          |             |
| Mesalamine Enema               |                        |          |             |
| Mesalamine ER                  |                        |          |             |
| Pentasa <sup>BvG<sup>          |                        |          |             |
| Sulfasalazine                  |                        |          |             |

### Non-Preferred

| Non-Preferred            | Generic Name              |         Quantity          | Time (Days) |
| :----------------------- | :------------------------ | :-----------------------: | :---------: |
| Dipentum                 |                           |                           |             |
| Mesalamine Supp          |                           |                           |             |
| Uceris Foam <sup>QL<sup> | Budesonide Aer 2 MG / ACT | Determined pursuant to PA |             |
| Zeposia                  |                           |                           |             |

## Authorizations

**Length of Authorizations**: 365 Days

**All Authorizations**: Must be prescribed in accordance with FDA approved labeling

## Criteria

### Non-Preferred

Non-Preferred Criteria

- Must provide documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances) **OR**
    - For any nonsolid oral dosage formulation: must provide documentation of medical necessity for why patient cannot be changed to a solid oral dosage formulation
- Must have had an inadequate clinical response of at least **30 days** with at least **two preferred** drugs
    - For non-preferred extended-release formulations: must provide documentation of an inadequate clinical response with its immediate release formulation (if available)
    - For non-preferred brand names that have preferred generics: must provide documentation of an inadequate clinical response or allergy to two or more generic labelers (if available)

### Subsequent Authorization

Subsequent Authorization Criteria

- Must provide documentation of patient's clinical response to treatment and ongoing safety monitoring

**QL** - Budesonide ER 9 MG tablets: 56 tablets per 90 days

## Links

[Criteria](https://pharmacy.medicaid.ohio.gov/sites/default/files/20230101_UPDL%20_Criteria_APPROVED.pdf#page=68)

[Preferred Drug List](https://pharmacy.medicaid.ohio.gov/sites/default/files/20230101_UPDL_APPROVED_12.13.22.pdf#page=24)

[Quantity Limit List](https://pharmacy.medicaid.ohio.gov/sites/default/files/20230101_Ohio_Medicaid_Quantity_Document_APPROVED.pdf)
